EC Awards Agendia Grant to Study Colorectal Cancer Therapies

Molecular diagnostics firm Agendia and several of its European partners have secured a $6.8 million grant from the European Commission to study targeted therapies for colorectal cancer and identify the disease’s certain subtypes.

Using diagnostic technology, the companies will determine if the therapies are more effective than existing ones that are not keyed to a tumor's subtype by testing therapies matched to the molecular subtype of each patient's tumor.

The project will take four years and involve Phase 2 studies across Europe for the treatment of molecular subgroups of colorectal cancer patients with advanced disease. — Michael Cipriano